factor VIIa

Brand names: Sevenfact · Active ingredient: Coagulation Factor Viia Recombinant Human

In short: SEVENFACT is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors. Limitation s of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency.

Forms & strengthsSEVENFACT is a white to off-white lyophilized powder for reconstitution in a colorless solution for injection. It is supplied in single-dose vial sizes containing 1 mg, 2 mg or 5 mg of coagulation factor VIIa (recombinant)-jncw. …
LabelLaboratoire Français du Fractionnement et des Biotechnologies Société Anonyme (LFB S.A.)
Label updatedOct 12, 2026

What is factor VIIa used for?

SEVENFACT is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors.

Limitation

s

of Use:

SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency.

âš  Boxed warning (FDA's strongest warning)

â—Ź

Serious arterial and venous thrombotic events may occur following administration of SEVENFACT

®

.

â—Ź

Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive SEVENFACT

®

.

â—Ź Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

factor VIIa dosage

For intravenous use after reconstitution only.

Dose and duration of SEVENFACT depend on the location and severity of the bleeding, need for urgent hemostasis, frequency of administration, and known patient responsiveness to FVIIa-containing bypassing agents during prior bleeding events. Treatment with SEVENFACT should be initiated as soon as a bleeding event occurs.

The dose, frequency, and duration of SEVENFACT therapy should be based on the patient’s clinical response and hemostasis evaluation.

The use of laboratory assessment(s) of coagulation (PT/INR, aPTT, FVII:C) does not necessarily correlate with or predict the hemostatic effectiveness of SEVENFACT.

Dose adjustment may be required if the patient has received other procoagulant therapies prior to treatment with SEVENFACT.

Based on the clinical trial program for SEVENFACT, the recommended initial dose should be adjusted based on the criteria provided in Table 1.

Type of Bleeding | Dosing Regimen Recommendation | Duration of Therapy

Mild and Moderate

Joint, superficial muscle, soft tissue and mucous membranes. | 75 mcg/kg repeated every 3 hours until hemostasis is achieved

or

Initial dose of 225 mcg/kg. If hemostasis is not achieved within 9 hours, additional 75 mcg/kg doses may be administered every 3 hours as needed to achieve hemostasis.

Consider alternative treatments if successful control of bleeding does not occur within 24 hours of the first administration of SEVENFACT. | Continue therapy to support healing and prevent recurrent hemorrhage after hemostasis to maintain the hemostatic plug.

The site and severity of bleeding should determine therapy duration.

Severe

Life or limb threatening hemorrhage, iliopsoas and deep muscle with neurovascular injury, retroperitoneum, intracranial, or gastrointestinal.Patients should seek immediate medical care if signs or symptoms of severe bleeding occur in the home setting. | 225 mcg/kg initially, followed if necessary 6 hours later with 75 mcg/kg every 2 hours until hemostasis is achieved.

Subsequent Dosing:After achieving hemostasis, base the decision for dosing on clinical assessment and the type of bleeding. Consider the risk of thrombosis with subsequent dosing after achieving hemostatic efficacy. | Continue therapy to support healing and prevent recurrent hemorrhage.

The site and severity of bleeding and the use of other procoagulant therapies should determine therapy duration.

Follow the procedures below for reconstitution of SEVENFACT.

Calculate the amount of SEVENFACT required and select the appropriate SEVENFACT packages containing the matching pre-filled syringe of sterile Water for Injection, and the vial adapters.

Reconstitute each vial with the pre-filled syringe provided with each vial of SEVENFACT. …

How to take factor VIIa — instructions & advice from the label

Advise patients:

to read the FDA-approved patient labeling (Patient Product Information and Instructions for Use).

about the early signs of hypersensitivity reactions and to seek medical help if the following occur:-

Hives, itching, rash, difficulty breathing, swelling around the mouth and throat, tightness of the chest, wheezing, dizziness or fainting, low blood pressure, or other symptoms of anaphylaxis.

about the signs of thrombosis and to seek medical help if the following occur:-

New-onset swelling and pain in the limbs or abdomen, new-onset chest pain, shortness of breath, loss of sensation or motor power, or altered consciousness or speech.

Revised: November 13, 2025U.S. License Number: 2061“SEVENFACT” is a registered trademark of LFB S.A.PATENT Information: https://hemabiodup.wpengine.com/patents/

For

I

nformation

C

ontact

:

Call: 855.718.HEMA (4362)Email: medinfo@hemabio.com

Manufacture

d by

:

Laboratoire Français du Fractionnement et des Biotechnologies S.A. (LFB S.A.)Puteaux, 92800 France

U.S. License Number: 2061

Distributed

by:

HEMA BiologicsLouisville, KY 40241

U.S. License Number: 2061

Warnings & precautions

Do not take this medicine if: SEVENFACT is contraindicated in patients with:

known allergy to rabbits or rabbit proteins. Exposure to SEVENFACT in these patients can result in severe hypersensitivity reaction.

severe hypersensitivity reaction to SEVENFACT or any of its components. Exposure to SEVENFACT in these patients can result in severe hypersensitivity reaction.

Serious arterial and venous thrombosis can occur with coagulation factor VIIa containing products including SEVENFACT.

The following patients may have increased risk of thrombosis with use of SEVENFACT:

History of congenital or acquired hemophilia receiving concomitant treatment with aPCC/PCC (activated or non-activated prothrombin complex) or other hemostatic agents

History of atherosclerotic disease, coronary artery disease, cerebrovascular disease, crush injury, septicemia, or thromboembolism.

Monitor patients who receive SEVENFACT for the development of signs and symptoms of activation of the coagulation system or thrombosis. When there is laboratory confirmation of intravascular coagulation or presence of clinical thrombosis, reduce the dose of SEVENFACT or stop treatment, depending on the patient’s condition.

Hypersensitivity and infusion-related reactions including anaphylaxis can occur with coagulation factor VIIa containing products including SEVENFACT. Sign and symptoms may include hives, itching, rash, difficulty breathing, swelling around the mouth and throat, tightness of the chest, wheezing, dizziness or fainting, and low blood pressure. Patients with known IgE-based hypersensitivity to casein may be at higher risk of hypersensitivity reactions. In the event of hypersensitivity or infusion-related reactions, discontinue SEVENFACT and manage according to clinical practice guideline.

Neutralizing antibodies may occur with the use of SEVENFACT. …

factor VIIa side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety database described in this section reflect exposure to SEVENFACT in two clinical studies, Study 1 and Study 2. A total of 42 patients with Hemophilia A or B with or without inhibitors received SEVENFACT: 27 patients in Study 1 at doses 75 mcg/kg and 225 mcg/kg and 15 patients in Study 2 at three escalating dose levels 25 mcg/kg, 75 mcg/kg and 225 mcg/kg

.

The most common adverse reactions (incidence ≥1%) reported in clinical trials for SEVENFACT were headache, dizziness, infusion-site discomfort, infusion-site hematoma, infusion-related reaction, and fever.

Adverse reactions reported in the two clinical studies are shown in Table 2. …

Drug interactions

Clinical experience with pharmacologic use of FVIIa-containing products indicates an elevated risk of serious thrombotic events when used simultaneously with activated prothrombin complex concentrates.

About this medicine

SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is a sterile, white to off-white lyophilized powder in a single-dose vial containing either 1 mg, 2 mg or 5 mg of coagulation factor VIIa (recombinant)-jncw as the active ingredient. SEVENFACT is to be reconstituted with Sterile Water for Injection in a pre-filled syringe supplied with the product. The reconstituted product is a clear to slightly opaque solution of coagulation factor VIIa (recombinant)-jncw at a concentration of 1 mg of protein per mL with a pH of approximately 6.0. SEVENFACT is formulated with arginine, isoleucine, citrate, glycine, lysine and polysorbate 80. It does not contain any antimicrobial preservatives nor human or bovine plasma-derived proteins.

The active ingredient in SEVENFACT, activated coagulation Factor VII, is a glycoprotein of 406 amino acids with a molecular weight of approximately 50 kilodaltons. The amino acid sequence of activated coagulation Factor VII is identical to that of human plasma-derived Factor VIIa. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b23ad666-8ce0-4e0b-9eff-c6983ac5f7e6. Read the full official label on DailyMed.